BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 35323374)

  • 1. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
    Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K
    Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
    Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia.
    Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK
    Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
    Mack PC; Banks KC; Espenschied CR; Burich RA; Zill OA; Lee CE; Riess JW; Mortimer SA; Talasaz A; Lanman RB; Gandara DR
    Cancer; 2020 Jul; 126(14):3219-3228. PubMed ID: 32365229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
    Sueoka-Aragane N; Nakashima C; Yoshida H; Matsumoto N; Iwanaga K; Ebi N; Nishiyama A; Yatera K; Kuyama S; Fukuda M; Ushijima S; Umeguchi H; Harada D; Kashiwabara K; Suetsugu T; Fujimoto N; Tanaka F; Uramoto H; Yoshii C; Nakatomi K; Koh G; Seki N; Aoe K; Nosaki K; Inoue K; Takamori A; Kawaguchi A
    Cancer Med; 2021 Jun; 10(12):3873-3885. PubMed ID: 33982444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
    Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ
    JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 11. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
    J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
    Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
    Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
    Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
    Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
    Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
    Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characteristics and prognostic factors of leptomeningeal metastasis in non-small cell lung cancer.
    Liu X; Li G; Zhang H; Chang Q; Fang M; Lu C; Tian P; Mei F
    Clin Neurol Neurosurg; 2023 Feb; 225():107572. PubMed ID: 36610238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.